$1.130
+0.010 (+0.89%)收盤時
SBFM 資訊
SBFM 事件
Sunshine Biopharma Receives Approval for Atenolol Tablets
Sunshine Biopharma announced the approval of its Atenolol tablets of 25mg, 50mg and 100mg for the Canadian market. Atenolol is the generic equivalent of the brand name, Tenormin. Atenolol belongs to a class of drugs known as beta-blockers. It works by blocking the action of certain natural chemicals in the body, such as epinephrine, on the heart and blood vessels. This effect lowers the heart rate, blood pressure, and strain on the heart. Atenolol is primarily indicated for: Hypertension Management: Lowering high blood pressure to help prevent strokes, heart attacks, and kidney problems. Angina Pectoris: Treating chest pain caused by reduced blood flow to the heart muscle. Post-Myocardial Infarction: Improving survival rates when administered clinically following a heart attack. It is anticipated that Sunshine Biopharma's Atenolol will be ready to ship to pharmacies by the end of 2026.
Sunshine Biopharma Files to Sell 24.48M Shares of Common Stock
Sunshine Biopharma files to sell 24.48M shares of common stock
Sunshine Biopharma Updates on K1.1 Project Progress
Sunshine Biopharma provided an update and outlined next plans for its oncology project, the K1.1 mRNA lipid nanoparticle program. The gene encoding the K1.1 mRNA is a tumor suppressor that is frequently mutated in a variety of cancers, including hepatocellular carcinoma, non-small cell lung cancer, and pancreatic cancer. Mutations in the gene of K1.1 mRNA create "cold" tumors that evade host immunosurveillance. In NSCLC and pancreatic cancers, a limited set of oncogenes is predominantly associated with mutations in the K1.1 gene, contributing to poor treatment prognosis. "Our results to date have demonstrated that the K1.1 mRNA LNP can be successfully delivered systemically in vivo. K1.1 mRNA has been shown to be well tolerated and capable of restoring expression of the target tumor suppressor in grafted liver tumors in a dose dependent manner. Proof of concept studies further indicated that K1.1 mRNA exhibits tumor suppressing activity in vivo as a single agent in at least two orthotopic HCC mouse models," the company said.
Sunshine Biopharma Receives Approval for Generic Enalapril in Canada
Sunshine Biopharma announces the approval of its generic Enalapril tablets 2.5mg, 5mg, 10mg and 20mg for the Canadian market. Enalapril is the generic equivalent of the brand name, Vasotec.
Sunshine Biopharma Approves 2mg Generic Dienogest for Canada
Sunshine Biopharma announce the approval of its generic Dienogest tablets of 2mg for the Canadian market. Dienogest is the generic equivalent of the brand name, Visanne Dienogest works through progesterone receptor binding, local anti-inflammatory actions, and mild hormone suppression. It reduces endometriosis pain by shrinking abnormal tissue growth.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。